La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Performant Healthcare a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Performant Healthcare..

Performant Healthcare (NASDAQ:PHLT) Azioni, Catena delle Opzioni

Performant Healthcare

Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.

Performant Healthcare, Inc. - Common Stock

Performant Healthcare Inc

Imagica Group Inc

This is the initial public offering of shares of common stock of Firefly Aerospace Inc. We are offering 16,200,000&nbsp;shares of common stock.
Prior to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price for our common stock will be between $41.00 and $43.00 per share. We have applied to list our common stock on The Nasdaq Global Market, or Nasdaq, under the symbol "FLY." However, no assurance can be given that our listing application will be approved. If our listing application is not approved by Nasdaq, we will not be able to consummate this offering.

News

IPOs

Firefly Aerospace Files For IPO Of 16.2M Shares, Targeting $41-$43 Per Share

Gyrodyne, LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRO#NASDAQ">GYRO</a>), an owner and manager of a diversified portfolio of real estate properties, today announced that its subsidiary, GSD Flowerfield, LLC, has entered into a purchase and sale agreement (the "Agreement") for the sale of approximately 49 acres of vacant land located within the Company's Flowerfield complex in St. James, New York (the "Property") to B2K Smithtown LLC ("B2K").
The Agreement sets a purchase price range of $24,000,000 to $28,740,000, with the final amount subject to certain conditions and contingencies, and based on current information, the Company estimates the final price to be $28,740,000. &nbsp;&nbsp;
As a result of the Agreement and associated assumptions, including anticipated site plan approval and additional projected costs incurred in connection with the revised liquidation timeline, the Company currently estimates its net asset value in liquidation ("NAV") as of June 30, 2025, to be approximately $32.6 million, with an estimated NAV per share of $14.83, an increase in NAV of $1.8 million or $0.84 per share. This represents an approximate 6% increase over the NAV reported in the first quarter 10-Q of $30.8 million or $14.01 per share.

Asset Sales

GYRO

Gyrodyne's  GSD Flowerfield Agrees To Sell 49 Acres In Flowerfield For Up To $28.74M

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is back above the 20 cents market, sparking <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">renewed optimism among traders</a>.
What Happened: In an update in his exclusive Patreon group, prominent analyst Kevin pointed out that DOGE rebounded from $0.189, a confluence of the 0.5 Fibonacci level and the weekly bull market support band.
He says that to confirm a short-term recovery, DOGE needs to reclaim the $0.22 level, which would place it above both the 4-hour and daily 200 SMA/EMA. Momentum indicators are turning bullish, suggesting a potential higher low forming on the higher time frames.
However, Kevin also cautions that Dogecoin's fate is tied to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) holding current levels and breaking above the $120,000–$123,000 zone to invalidate the ongoing weekly bearish divergence.
Trader Cantonese Cat <a href="https://x.com/cantonmeow/status/1952059860532474139">said</a> he has increased his DOGE holdings, citing a favorable risk-reward setup. He expects a bull market support band backtest along with a breakout and retest of a long-term bear market trendline, reinforcing his bullish stance.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46685084/dogecoin-drops-15-in-1-week-why-do-whales-keep-buying-the-dip">Dogecoin Drops 15% In 1 Week: Why Do Whales Keep Buying The Dip?</a>
What's Next: XForceGlobal <a href="https://x.com/XForceGlobal/status/1952388948686463125">remains</a> optimistic, noting that DOGE is one of the few altcoins with a realistic shot at surpassing its previous all-time high in this cycle. He's focusing only on assets with strong return potential, and DOGE remains high on his list.
Trader Tardigrade draws parallels between DOGE's current pattern and a historical bullish setup. 
In the previous cycle, a 65% drop was followed by a triple bottom and a strong rally. 
Currently, DOGE has already retraced 73%, formed two clear bottoms, and is now developing a third.
If this pattern completes, it could trigger a major rally and signal a trend reversal.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a>/D3: In the previous structure, we observed a 65% drop followed by three bottoms in line and a decent surge. In the current structure, <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> has reached a 73% correction, which is considered sufficient. Two bottoms have been seen, and the formation of the third bottom is… <a href="https://t.co/11DrORcKOH">pic.twitter.com/11DrORcKOH</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1952331955804279089?ref_src=twsrc%5Etfw">August 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46823618/bitcoin-ethereum-xrp-dogecoin-continue-relief-rally-off-saturday-lows">Bitcoin, Ethereum, XRP, Dogecoin Continue Relief Rally Off Saturday Lows</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

Dogecoin Recovers Above 20 Cents: Where Is DOGE Headed Next?

Trading Ideas

Live On CNBC, Terranova ETF ( JOET) Announces Bought Morgan Stanley

Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) has outperformed the market over the past 20 years by 1.71% on an annualized basis producing an average annual return of 10.18%. Currently, Royal Caribbean Gr has a market capitalization of $86.29 billion. 
Buying $100 In RCL: If an investor had bought $100 of RCL stock 20 years ago, it would be worth $693.67 today based on a price of $317.67 for RCL at the time of writing.
<h3>Royal Caribbean Gr's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754325925_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Royal Caribbean Gr 20 Years Ago Would Be Worth This Much Today

On Monday, Replimune Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. 
Shares fell sharply Monday on heavy volume, capping a month-long slide of nearly 43%.
At last check, the stock is trading lower with a session volume of 15.96 million compared to the average volume of 7.87 million, as per data from <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Over the past month, the stock has declined by almost 43%.
The FDA&#8217;s top cancer drug regulator stepped in during the final stages of a heated review of Replimune&#8217;s skin cancer treatment — a move that played a key role in the drug being rejected at the last minute, despite support from some within the agency, STAT <a target="_blank" href="https://www.statnews.com/2025/08/04/replimune-skin-cancer-drug-rejection-pazdur-prasad/" rel="noreferrer noopener">has</a> learned.
Ongoing leadership changes, staff turnover, and internal issues at the FDA influenced the review process and the decision to deny approval.
Replimune found itself caught in the middle of the agency&#8217;s internal turmoil.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/06/39138772/moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-pati" target="_blank" rel="noreferrer noopener">Moderna, Merck Reveal Three-Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients</a>
Most recently, Vinay Prasad, the former director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER), resigned within <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46725571/whats-going-on-with-sarepta-capricor-and-other-gene-therapy-stocks-on-wednesday" rel="noreferrer noopener">three months of appointment</a>.
Dr. Prasad has openly criticized the biopharmaceutical industry and the FDA for using accelerated approvals broadly based on surrogate endpoints.
For the unversed, in July, Replimmune received an FDA Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with Bristol-Myers&nbsp;Squibb&nbsp;Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46544331/fda-rejects-replimunes-blood-cancer-drug-stock-sinks" rel="noreferrer noopener">(nivolumab) for advanced melanoma</a>.
The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">evidence of effectiveness</a>.
Furthermore, the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.
After the FDA update, Replimmune stock plummeted around 70%.
Soon after, the company was <a href="https://www.blockleviton.com/cases/repl" target="_blank" rel="noreferrer noopener">hit</a> with a lawsuit alleging it misled investors by overstating the prospects of its IGNYTE trial, despite knowing—or should have known—of issues that led the FDA to deem the study inadequate and poorly controlled. The complaint claims the company's statements about its business and outlook were materially false or lacked a reasonable basis.
The lawsuit claims that investors suffered damages when the true details entered the market.
Price Action: REPL stock is down 27.9% at $5.48 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/08/46831763/joby-stock-flies-on-blade-deal-and-military-edge-in-race-to-the-future" target="_blank" rel="noreferrer noopener">Joby Stock Flies On Blade Deal And Military Edge In Race To The Future</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Movers

General

REPL

Why Is Replimune Stock Trading Lower On Monday?

WIIM

INV stock has given up its prior gain. Innventure shares were trading higher after the company's Accelsius announced  membership in the NVIDIA Inception program.

<a href="https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research" title="https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research">https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research</a>

ARCT

GILD

GSKH

IMCR

SGMO

THTX

'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News

<a href="https://www.bloomberg.com/news/articles/2025-08-04/german-finance-chief-plans-to-ask-bessent-about-quotas-for-steel?srnd=homepage-americas" title="https://www.bloomberg.com/news/articles/2025-08-04/german-finance-chief-plans-to-ask-bessent-about-quotas-for-steel?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-08-04/german-finance-chief-plans-to-ask-bessent-about-quotas-for-steel?srnd=homepage-americas</a>

Macro Economic Events

Politics

Global

Economics

'German Finance Chief Plans to Ask Bessent About Quotas for Steel' - Bloomberg News

Schwab clients were net sellers of equities in July; Net selling was highest in the Information Technology sector while net-buying activity was seen in Communication Services, Health Care and Financials
The Schwab Trading Activity Index&#x2122; (STAX) increased to 41.79 in July, up from its score of 40.66 in June. The only index of its kind, the STAX is a proprietary, behavior-based index that analyzes retail investor stock positions and trading activity from Schwab's millions of client accounts to illuminate what investors were actually doing and how they were positioned in the markets each month.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250804565525/en/">https://www.businesswire.com/news/home/20250804565525/en/</a>
The reading for the four-week period ending July 25, 2025, ranks "low" compared to historic averages.

SCHW

The Schwab Trading Activity Index Increased To 41.79 In July, Up From Its Score Of 40.66 In June

Agreement builds on successful partnership in one of world's fastest growing economies
PPG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) today announced the extension of its joint venture agreement in India with Asian Paints Ltd. The 15-year renewal will allow the companies to continue serving the country's industrial, protective, marine, packaging, automotive and powder coatings customers with industry-leading solutions that solve customers' biggest challenges. The extension will take effect in 2026 and run through 2041.
&nbsp;
The partnership was established in 1997 with the formation of a 50-50 joint venture, PPG Asian Paints Private Ltd., to service the automotive, refinish, marine and consumer packaging markets. It was expanded in 2012 with the formation of a separate 50-50 joint venture, Asian Paints PPG Private Ltd., to service the protective and powder coatings market. Both joint ventures will continue to leverage PPG's technical expertise and global footprint. PPG will continue to have management control of PPG Asian Paints Private Ltd., and Asian Paints Ltd will have effective management control of Asian Paints PPG Private Ltd. to best utilize the companies' respective strengths.

Contracts

PPG And Asian Paints Extend 15-Year Joint Venture Agreement In India Through 2041

DA Davidson analyst Michael Baker maintains Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) with a Buy and raises the price target from $60 to $64.

Price Target

Analyst Ratings

DA Davidson Maintains Buy on Build-A-Bear Workshop, Raises Price Target to $64

COIN

HOOD

PYPL

Live On CNBC, Terranova ETF ( JOET) Announces Bought Block; Bought Robinhood Markets; Bought PayPal Holdings,; Bought Coinbase

BoA Securities analyst Justin Post maintained a Buy rating on Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) <a href="https://www.benzinga.com/quote/UBER/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price target</a> of $115 on Monday.
Post reiterated a bullish view on Uber ahead of its second-quarter earnings report on Aug. 6. It expects solid outperformance driven by strong Mobility and Delivery trends, favorable foreign exchange tailwinds and early signs of success in autonomous vehicle partnerships.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/07/46682004/weride-and-uber-expand-robotaxi-reach-in-abu-dhabi" target="_blank" rel="noreferrer noopener">WeRide And Uber Expand Robotaxi Reach In Abu Dhabi</a>
The analyst raised his second-quarter gross bookings forecast to $47.1 billion, 2% above the Street&#8217;s $46.4 billion. Revenue and adjusted EBITDA projections are at $12.56 billion and $2.12 billion, both slightly above consensus. He expects constant currency (CC) bookings growth of 19% year-over-year, ahead of the 18% consensus, supported by accelerating U.S. consumer spending and stronger international results, which are boosted by FX improvements.
In Mobility, Post projects 20% Y/Y CC growth, which is in line with first-quarter trends, and highlights accelerating transit spending, as seen in BAC aggregated card data. Although U.S. travel demand remained weak, he expects a recovery in the second half of 2025 to support future growth. He also pointed to Uber&#8217;s expanding autonomous vehicle ecosystem, citing partnerships with Lucid Group, Nuro, Baidu and Wayve, and noted that Uber&#8217;s Autonomous Vehicles (AV) operations in Atlanta and Austin are likely gaining traction.
For Delivery, Post forecasts 19% Y/Y growth excluding FX, slightly accelerating from the first quarter. He credits strong adoption of Uber One and new perks launched in the second quarter — such as 10% credits on Uber Rent and Lime rides and exclusive &#8220;Member Days&#8221; deals with major brands — as key drivers of membership and delivery volume growth. He also sees ongoing strength in Uber&#8217;s Advertising business, which grew 60% Y/Y in the first quarter.
Post expects the upcoming acquisition of Trendyol GO in Turkey to add another point to Delivery growth once it closes in the second half of 2025. He projects third-quarter bookings in the $47.25 billion–$48.75 billion range, implying 17% Y/Y growth at the midpoint and slight FX headwinds. His EBITDA forecast for the third quarter is $2.26 billion–$2.36 billion, bracketing consensus and implying a 9.7% incremental margin at the midpoint.
For full-year 2025, Post raised estimates to $190 billion in gross bookings, $51.1 billion in revenue, and $8.62 billion in EBITDA, all above Street expectations. He sees continued investment in Uber One and new product initiatives supporting medium-term growth.
Despite a 44% year-to-date stock gain, Post views Uber&#8217;s valuation as attractive. It trades at 17 times EV/EBITDA versus its four-year average of 22 times and 18 times free cash flow, well below FANG (Facebook parent Meta Platforms, Amazon, Netflix and Google parent Alphabet) peers&#8217; 43 times. He sees room for upside with an expected 2026 bottom-line growth rate of 26% versus 19% for FANG. The easing of AV-related overhang and Uber&#8217;s minimal exposure to import tariffs further support his positive stance.
UBER Price Action: UBER stock is up 1.10% at $87.89 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46774709/arm-ai-ambitions-are-growing-but-analysts-warn-of-margin-trouble-ahead" target="_blank" rel="noreferrer noopener">Arm AI Ambitions Grow, But Analysts Warn Of Margin Trouble Ahead</a></li>
</ul>

Reiteration

UBER

Why This Analyst Thinks Uber Is Set For A Strong Q2

DA Davidson analyst Brian Holland maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and raises the price target from $171 to $188.

DA Davidson Maintains Neutral on Hershey, Raises Price Target to $188

If you work at a regular job, chances are you make the same income each month. That level of predictability makes it easy to allocate each paycheck across various expenses. However, some people have volatile incomes that are based on seasonal changes, industrial trends, and other factors that are outside of their control.
It's a lot harder to budget if you make $8,000 in one month and proceed to earn $3,000 in the following month. A <a href="https://www.reddit.com/r/personalfinance/comments/1mbb3u1/how_do_you_budget_when_your_income_fluctuates/">volatile income</a> can be rewarding since some side hustles and freelance opportunities have greater earning potential. However, you still have to manage your expenses despite a volatile income. This conversation came up on Reddit, and several people with volatile incomes came forward with their advice.
Don't Miss:
<ul class="wp-block-list">
<li>Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can <a href="https://www.benzinga.com/money/mode-mobile-2">invest today for just $0.30/share.</a></li>
</ul>
<h2 class="wp-block-heading">Use Your Average Monthly Earnings</h2>
One of the top comments came from a Redditor who suggested using your average monthly earnings when creating a budget. People with volatile incomes will have some lower-earning months, which will make it more difficult to make ends meet. However, if you save extra money during your best months, you can establish a solid emergency fund.
An emergency fund offers a financial cushion during your slower months. You can put your money into a high-yield savings account that generates close to 4.00% APY while letting you access your funds whenever you need them.&nbsp;
Many financial experts recommend having six months of living expenses stored in your emergency savings account. You may have to pull some money from this account during slower months, but actively building this fund during better months will prepare you for any slowdowns.&nbsp;
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
<h2 class="wp-block-heading">Construct Your Budget Around Your Worst Month</h2>
Some Redditors suggested determining how much you earn during your worst month and building your budget around that figure. This decision will require that you live well below your means, especially if your income has dramatic monthly swings.&nbsp;
However, if your living expenses reflect your worst month, you will have plenty of excess during your best months. It may be more realistic to use your second-worst or third-worst month when calculating your budget, in case you have one really bad month.
You don't have to use your worst month as a budgeting gauge forever. The Redditor who suggested this approach said that you can save the extra money at the end of each month. If you invest that money, your assets will grow over time and give you more options. Enduring short-term sacrifices with a firm budget can result in attractive long-term gains and a better retirement.
See Also: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
<h2 class="wp-block-heading">Look For Growth Opportunities</h2>
A volatile income makes it less predictable to plan your monthly expenses, but you don't have to settle with your current earnings. More volatility can also pave the way for more opportunities. Service providers can continue to prospect and seek new income streams that keep them busy.
The best way to create a budget that you can maintain is by regularly looking for ways to boost your income. It's good to be defensive by tracking your expenses and setting limits on how much you can spend. However, if you only play defense, you will miss out on income growth.
If you can gradually increase your income while maintaining your current lifestyle, budgeting will get a lot easier. You will give yourself a bigger cushion as your income grows and your expenses stay the same. Always look for new opportunities.
Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Image: Shutterstock

Personal Finance

No Steady Paycheck? Here's How Real People Budget With Volatile Incomes—And Stay Financially Sane

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and lowers the price target from $45 to $40.

CMPS

HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $40

Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) has outperformed the market over the past 10 years by 4.0% on an annualized basis producing an average annual return of 15.68%. Currently, Tyler Technologies has a market capitalization of $25.16 billion. 
Buying $100 In TYL: If an investor had bought $100 of TYL stock 10 years ago, it would be worth $425.47 today based on a price of $581.65 for TYL at the time of writing.
<h3>Tyler Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754325020_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

RH shares are trading higher in sympathy with Wayfair, which reported better-than-expected Q2 financial results.

DA Davidson analyst Kurt Yinger maintains BlueLinx Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXC#NYSE">BXC</a>) with a Neutral and lowers the price target from $80 to $75.

DA Davidson Maintains Neutral on BlueLinx Hldgs, Lowers Price Target to $75

Press Releases

Performant Healthcare, Inc. Announces Financial Results for Fourth Quarter and Full Year 2024

Performant Survey Spotlights Top Healthcare Technology Initiatives

Performant Healthcare, Inc. to Report First Quarter 2025 Earnings on May 8, 2025

Performant Healthcare, Inc. Announces Financial Results for First Quarter 2025

Performant to Participate in B Riley Securities' 25th Annual Institutional Investor Conference

Performant Healthcare, Inc. to Report Second Quarter 2025 Earnings on August 5, 2025

Performant Healthcare, Inc. to Be Acquired by Machinify

Performant Healthcare, Inc. Announces Preliminary Financial Results for Second Quarter 2025

PHLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Performant Healthcare, Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm investigates whether Performant Healthcare Inc. is obtaining a Fair Price for its Public Shareholders

PHLT

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Tangible Equity Unit

BrightSpring Health

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Performant Healthcare

Performant Healthcare (PHLT) Opzioni

Performant Healthcare (NASDAQ:PHLT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO